Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7112592 | ALLERGAN | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents |
Jan, 2026
(2 years from now) | |
US8471025 | ALLERGAN | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Aug, 2031
(8 years from now) | |
US9695122 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) | |
US8969566 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) | |
US9284314 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7612087 | ALLERGAN | Heterocyclic compounds as inhibitors of beta-lactamases |
Nov, 2026
(3 years from now) | |
US8835455 | ALLERGAN | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Oct, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 25, 2020 |
New Patient Population (NPP) | Dec 20, 2025 |
Generating Antibiotic Incentives Now (GAIN) | Feb 25, 2025 |
Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient
NCE-1 date: 2024-02-26
Market Authorisation Date: 25 February, 2015
Treatment: A method of treating bacterial infections in complicated intra-abdominal infection and complicated urinary tract infection, including pyelonephritis, patients comprising administering a bactericidally...
Dosage: POWDER;INTRAVENOUS
22
United States
9
China
9
Japan
8
European Union
7
Brazil
7
Korea, Republic of
6
Spain
5
Hong Kong
5
France
5
Israel
5
Australia
4
Denmark
4
Poland
4
Russia
4
Canada
4
Argentina
4
Portugal
4
Mexico
4
Slovenia
3
Malaysia
3
Norway
3
Cyprus
3
Taiwan
3
Costa Rica
3
Hungary
2
Austria
2
Turkey
2
Germany
2
Yugoslavia
2
Ukraine
2
Morocco
2
EA
2
OA
2
ME
2
New Zealand
2
Croatia
2
Ecuador
2
South Africa
1
Uruguay
1
AP
1
Czech Republic
1
United Kingdom
1
Estonia
1
Singapore
1
Belgium
1
Peru
1
Chile
1
Jordan
1
Algeria
1
Bulgaria
1
Netherlands
1
Slovakia
1
Colombia
1
Lithuania
1
Tunisia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9944651 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to kit |
Oct, 2034
(11 years from now) | |
US9200002 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to KIT |
Oct, 2034
(11 years from now) | |
US9994575 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to kit |
Oct, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 9, 2025 |
New Indication (I) | Jun 16, 2024 |
Orphan Drug Exclusivity (ODE) | Jan 9, 2027 |
Drugs and Companies using AVAPRITINIB ingredient
NCE-1 date: 2024-01-10
Market Authorisation Date: 09 January, 2020
Treatment: Treatment of unresectable or metastatic gastrointestinal stromal tumor (gist) harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation; Treatment of advanced systemic mastoc...
Dosage: TABLET;ORAL
9
United States
3
Hungary
2
Spain
2
Poland
2
China
2
Japan
2
Portugal
2
Lithuania
2
European Union
1
Uruguay
1
Hong Kong
1
Philippines
1
Denmark
1
RS
1
Russia
1
Brazil
1
Canada
1
Singapore
1
Argentina
1
Norway
1
New Zealand
1
Croatia
1
Korea, Republic of
1
Cyprus
1
Israel
1
Taiwan
1
Mexico
1
Australia
1
Netherlands
1
South Africa
1
Slovenia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10525033 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(7 years from now) | |
US9889118 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(7 years from now) | |
US9545426 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(7 years from now) | |
US9084765 | ACACIA | Use of amisulpride as an anti-emetic |
Feb, 2034
(10 years from now) | |
US11357753 | ACACIA | Rescue treatment of post operative nausea and vomiting |
Feb, 2038
(14 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 26, 2025 |
Drugs and Companies using AMISULPRIDE ingredient
NCE-1 date: 2024-02-27
Market Authorisation Date: 26 February, 2020
Treatment: Treatment of post-operative nausea and vomiting; Prevention of post-operative nausea and vomiting
Dosage: SOLUTION;INTRAVENOUS
11
United States
4
United Kingdom
4
European Union
3
Spain
3
Denmark
3
RS
3
Poland
3
Japan
3
Croatia
3
Cyprus
3
Israel
3
Portugal
3
Mexico
3
Slovenia
2
China
2
Brazil
2
Canada
2
EA
2
San Marino
2
Korea, Republic of
2
Australia
1
Hong Kong
1
Norway
1
New Zealand
1
Lithuania
1
Hungary
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10472365 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(4 years from now) | |
US9777007 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(4 years from now) | |
US9914738 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(4 years from now) | |
US10961250 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(4 years from now) | |
US10195210 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Nov, 2031
(8 years from now) | |
US10342800 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Nov, 2031
(8 years from now) | |
US10722522 | ACACIA | Dosing regimen for sedation with CNS 7056 (remimazolam) |
Nov, 2031
(8 years from now) | |
US9737547 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Nov, 2031
(8 years from now) | |
US10052334 | ACACIA | Dosing regimen for sedation with CNS 7056 (remimazolam) |
Nov, 2031
(8 years from now) | |
US9827251 | ACACIA | Dosing regimen for sedation with CNS 7056 (remimazolam) |
Nov, 2031
(8 years from now) | |
US9561236 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Apr, 2033
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Oct 6, 2025 |
Drugs and Companies using REMIMAZOLAM BESYLATE ingredient
NCE-1 date: 2024-10-06
Market Authorisation Date: 06 October, 2020
Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less
Dosage: POWDER;INTRAVENOUS
16
United States
8
European Union
5
China
4
Hong Kong
4
Korea, Republic of
3
United Kingdom
3
Japan
2
Spain
2
Denmark
2
Poland
2
Portugal
2
Australia
2
Slovenia
1
Austria
1
RS
1
Germany
1
Russia
1
Brazil
1
Canada
1
EA
1
Croatia
1
Mexico
1
Lithuania
1
Hungary
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8268848 | EISAI INC | Cyclopropane compound |
Sep, 2031
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10188652 | EISAI INC | Compositions and methods for treating insomnia |
Oct, 2035
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 7, 2025 |
Drugs and Companies using LEMBOREXANT ingredient
NCE-1 date: 2024-04-07
Market Authorisation Date: 07 April, 2020
Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance
Dosage: TABLET;ORAL
8
United States
5
Japan
3
Singapore
2
Spain
2
Russia
2
China
2
Brazil
2
Canada
2
Korea, Republic of
2
Israel
2
Mexico
2
Australia
2
European Union
1
Hong Kong
1
Malaysia
1
Denmark
1
RS
1
Poland
1
Ukraine
1
Morocco
1
Argentina
1
New Zealand
1
Croatia
1
Cyprus
1
Peru
1
Chile
1
Portugal
1
Taiwan
1
Jordan
1
Colombia
1
Tunisia
1
Slovenia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10383961 | RADIOMEDIX | PET tracer for imaging of neuroendocrine tumors |
Aug, 2032
(9 years from now) | |
US10159759 | RADIOMEDIX | Pet tracer for imaging of neuroendocrine tumors |
Aug, 2032
(9 years from now) | |
US11160888 | RADIOMEDIX | PET tracer for imaging of neuroendocrine tumors |
Aug, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 3, 2025 |
Orphan Drug Exclusivity (ODE) | Sep 3, 2027 |
Drugs and Companies using COPPER DOTATATE CU-64 ingredient
NCE-1 date: 2024-09-03
Market Authorisation Date: 03 September, 2020
Treatment: Use of cu-64 dotatate with positron emission tomography (pet) for localization of somatostatin receptor positive neuroendocrine tumors (nets) in adult patients
Dosage: SOLUTION;INTRAVENOUS
6
United States
4
Denmark
2
Poland
2
Spain
2
Hungary
2
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9186344 | ULTRAGENYX PHARM INC | Glycogen or polysaccharide storage disease treatment method |
Jul, 2025
(2 years from now) | |
US8697748 | ULTRAGENYX PHARM INC | Glycogen or polysaccharide storage disease treatment method |
Oct, 2025
(2 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 30, 2027 |
New Chemical Entity Exclusivity (NCE) | Jun 30, 2025 |
Drugs and Companies using TRIHEPTANOIN ingredient
NCE-1 date: 2024-06-30
Market Authorisation Date: 30 June, 2020
Treatment: NA
Dosage: LIQUID;ORAL
11
United States
3
Canada
2
Mexico
2
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9586955 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
Feb, 2033
(9 years from now) | |
US9969754 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
May, 2035
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11534444 | GENENTECH INC | Treatment of SMA |
Oct, 2038
(15 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | May 27, 2029 |
New Chemical Entity Exclusivity (NCE) | Aug 7, 2025 |
New Patient Population (NPP) | May 27, 2025 |
Drugs and Companies using RISDIPLAM ingredient
NCE-1 date: 2024-08-07
Market Authorisation Date: 07 August, 2020
Treatment: Treatment of spinal muscular atrophy
Dosage: FOR SOLUTION;ORAL
12
United States
5
European Union
4
EA
4
Korea, Republic of
4
Israel
3
Philippines
3
China
3
Morocco
3
Singapore
3
Japan
3
Taiwan
3
Australia
3
Hungary
2
Spain
2
Denmark
2
Poland
2
Brazil
2
Canada
2
Ukraine
2
Argentina
2
New Zealand
2
Peru
2
Chile
2
Mexico
2
Costa Rica
1
Hong Kong
1
Turkey
1
RS
1
Norway
1
Croatia
1
Portugal
1
Ecuador
1
Netherlands
1
South Africa
1
Colombia
1
Lithuania
1
Slovenia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10030005 | GENENTECH INC | Inhibitors of RET |
Nov, 2036
(13 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11273160 | GENENTECH INC | RET inhibitor for use in treating cancer having a RET alteration |
Apr, 2039
(15 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 4, 2025 |
Orphan Drug Exclusivity (ODE) | Sep 4, 2027 |
Drugs and Companies using PRALSETINIB ingredient
NCE-1 date: 2024-09-04
Market Authorisation Date: 04 September, 2020
Treatment: Treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detected by an fda approved test; Treatment of adult and pediatri...
Dosage: CAPSULE;ORAL
19
United States
6
Japan
3
China
3
Israel
3
European Union
2
Brazil
2
Canada
2
Singapore
2
Korea, Republic of
2
Chile
2
Australia
1
Hong Kong
1
Philippines
1
Russia
1
Morocco
1
Argentina
1
EA
1
Peru
1
Taiwan
1
Mexico
1
Costa Rica
1
Ecuador
1
South Africa
1
Saudi Arabia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8653260 | UROVANT | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists |
Apr, 2029
(5 years from now) | |
US8247415 | UROVANT | Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists |
Dec, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 23, 2025 |
Drugs and Companies using VIBEGRON ingredient
NCE-1 date: 2024-12-23
Market Authorisation Date: 23 December, 2020
Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency
Dosage: TABLET;ORAL
8
United States
3
Japan
3
Korea, Republic of
2
Dominican Republic
2
China
2
Costa Rica
1
Spain
1
Austria
1
Hong Kong
1
Denmark
1
RS
1
Poland
1
Brazil
1
Canada
1
Ukraine
1
Singapore
1
Morocco
1
Argentina
1
EA
1
ME
1
Nicaragua
1
New Zealand
1
Honduras
1
Croatia
1
Cyprus
1
Peru
1
Chile
1
Israel
1
Portugal
1
El Salvador
1
Taiwan
1
Georgia
1
Mexico
1
Australia
1
Ecuador
1
South Africa
1
Colombia
1
Tunisia
1
Slovenia
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9458195 | RHYTHM | Melanocortin receptor ligands |
Oct, 2027
(4 years from now) | |
US8039435 | RHYTHM | Melanocortin receptor ligands |
Oct, 2027
(4 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11129869 | RHYTHM | Pharmaceutical compositions |
Jul, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 16, 2029 |
New Chemical Entity Exclusivity (NCE) | Nov 25, 2025 |
New Indication (I) | Jun 16, 2025 |
Drugs and Companies using SETMELANOTIDE ACETATE ingredient
NCE-1 date: 2024-11-25
Market Authorisation Date: 25 November, 2020
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
16
United States
8
European Union
7
Japan
5
Spain
5
Denmark
5
Poland
5
China
5
Israel
5
Portugal
5
Australia
4
Hong Kong
4
Russia
4
Canada
4
Hungary
3
Korea, Republic of
2
New Zealand
2
Netherlands
1
Brazil
1
Singapore
1
Slovenia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9567363 | OTSUKA | Certain compounds, compositions and methods |
Oct, 2028
(5 years from now) | |
US8268800 | OTSUKA | Certain compounds, compositions and methods |
Aug, 2030
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8618075 | OTSUKA | Certain compounds, compositions and methods |
Oct, 2028
(5 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 7, 2025 |
Orphan Drug Exclusivity (ODE) | Jul 7, 2027 |
Drugs and Companies using CEDAZURIDINE; DECITABINE ingredient
NCE-1 date: 2024-07-07
Market Authorisation Date: 07 July, 2020
Treatment: Method for inhibiting cytidine deaminase by administering cedazuridine; Method for inhibiting degradation of a cda substrate by administering cedazuridine; Treatment of chronic myelomonocytic leukemia...
Dosage: TABLET;ORAL
6
United States
2
Spain
2
Japan
2
European Union
1
Hong Kong
1
Austria
1
Malaysia
1
Denmark
1
RS
1
Poland
1
China
1
Brazil
1
Canada
1
Ukraine
1
EA
1
ME
1
Nicaragua
1
New Zealand
1
Croatia
1
Korea, Republic of
1
Guatemala
1
Cyprus
1
Israel
1
Portugal
1
Taiwan
1
Jordan
1
Mexico
1
Australia
1
Costa Rica
1
Ecuador
1
South Africa
1
Colombia
1
Saudi Arabia
1
Slovenia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8835646 | RECORDATI RARE | Organic compounds |
Aug, 2026
(3 years from now) | |
US8314097 | RECORDATI RARE | Organic compounds |
Mar, 2029
(5 years from now) | |
US9434754 | RECORDATI RARE | Use of an adrenal hormone-modifying agent |
Jan, 2031
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8609862 | RECORDATI RARE | Use of an adrenal hormone-modifying agent |
Jan, 2031
(7 years from now) | |
US10143680 | RECORDATI RARE | Pharmaceutical dosage forms |
Jul, 2035
(12 years from now) | |
US10709691 | RECORDATI RARE | Pharmaceutical dosage forms |
Oct, 2035
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 6, 2025 |
Orphan Drug Exclusivity (ODE) | Mar 6, 2027 |
Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient
NCE-1 date: 2024-03-06
Market Authorisation Date: 06 March, 2020
Treatment: Cushing's disease
Dosage: TABLET;ORAL
16
United States
8
Japan
7
European Union
5
China
5
Korea, Republic of
4
Spain
4
Mexico
3
Denmark
3
Poland
3
Canada
3
Singapore
3
EA
3
Croatia
3
Cyprus
3
Peru
3
Israel
3
Portugal
3
Taiwan
3
Australia
3
Lithuania
3
Tunisia
3
Slovenia
3
Hungary
2
Philippines
2
Brazil
2
Morocco
2
Argentina
2
Norway
2
New Zealand
2
Chile
2
Ecuador
2
South Africa
1
IB
1
Hong Kong
1
Malaysia
1
Turkey
1
RS
1
Russia
1
Ukraine
1
ME
1
Guatemala
1
Jordan
1
Netherlands
1
Luxembourg
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8236799 | ALMIRALL | Biaryl compositions and methods for modulating a kinase cascade |
Dec, 2025
(2 years from now) | |
US8980890 | ALMIRALL | Compositions and methods of treating cell proliferation disorders |
Dec, 2025
(2 years from now) | |
US7300931 | ALMIRALL | Compositions for treating cell proliferation disorders |
Feb, 2026
(2 years from now) | |
US7851470 | ALMIRALL | Composition and methods for modulating a kinase cascade |
Feb, 2029
(5 years from now) | |
US10669236 | ALMIRALL | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide |
Sep, 2038
(15 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10323001 | ALMIRALL | Compositions for modulating a kinase cascade and methods of use thereof |
Dec, 2027
(4 years from now) | |
US11497750 | ALMIRALL | Methods of treating and/or preventing actinic keratosis |
Mar, 2038
(14 years from now) | |
US10617693 | ALMIRALL | Methods of treating and/or preventing actinic keratosis |
Mar, 2038
(14 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 14, 2025 |
Drugs and Companies using TIRBANIBULIN ingredient
NCE-1 date: 2024-12-14
Market Authorisation Date: 14 December, 2020
Treatment: Topical treatment of actinic keratosis of the face or scalp
Dosage: OINTMENT;TOPICAL
54
United States
12
Japan
9
China
6
Canada
6
Australia
6
European Union
4
Spain
4
Denmark
4
Korea, Republic of
4
Israel
4
Taiwan
3
Hong Kong
3
Russia
3
Brazil
2
Singapore
2
Cyprus
2
Mexico
1
Austria
1
Malaysia
1
Poland
1
Portugal
1
Netherlands
1
South Africa
1
Slovenia
1
Hungary
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8178693 | ASTRAZENECA | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2023
(2 months ago) | |
US7425637 | ASTRAZENECA | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2024
(9 months from now) | |
US9156795 | ASTRAZENECA | Hydrogen sulfate salt |
Dec, 2026
(3 years from now) | |
US9562017 | ASTRAZENECA | Hydrogen sulfate salt |
Dec, 2026
(3 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 10, 2025 |
Orphan Drug Exclusivity (ODE) | Apr 10, 2027 |
Drugs and Companies using SELUMETINIB SULFATE ingredient
NCE-1 date: 2024-04-10
Market Authorisation Date: 10 April, 2020
Treatment: Treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn)
Dosage: CAPSULE;ORAL
24
United States
7
Spain
7
China
7
European Union
6
Poland
6
Japan
5
Iceland
5
Denmark
5
Brazil
5
Argentina
5
Korea, Republic of
5
Cyprus
5
Israel
5
Portugal
5
Taiwan
5
Slovenia
4
Hong Kong
4
Dominican Republic
4
Australia
3
Russia
3
Canada
3
Singapore
3
Mexico
3
South Africa
3
Hungary
2
Ukraine
2
New Zealand
2
Chile
2
Netherlands
2
Lithuania
1
Panama
1
Austria
1
Malaysia
1
RS
1
Germany
1
Norway
1
Croatia
1
Belgium
1
Ecuador
1
Luxembourg
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7300935 | MYOVANT SCIENCES | Thienopyrimidine compounds and use thereof |
Jan, 2024
(8 months from now) | |
US8058280 | MYOVANT SCIENCES | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
Jan, 2024
(8 months from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9346822 | MYOVANT SCIENCES | Thienopyrimidine compounds and use thereof |
Feb, 2024
(8 months from now) | |
US11033551 | MYOVANT SCIENCES | Methods of treating uterine fibroids |
Sep, 2037
(14 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 18, 2025 |
New Product (NP) | May 26, 2024 |
M (M) | Jan 27, 2026 |
New Indication (I) | Aug 5, 2025 |
Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient
NCE-1 date: 2024-12-18
Market Authorisation Date: 26 May, 2021
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women
Dosage: TABLET;ORAL
20
United States
8
Japan
8
European Union
5
Australia
4
China
4
Canada
4
Israel
3
Brazil
3
Morocco
3
Argentina
3
EA
3
New Zealand
3
Mexico
2
Spain
2
Denmark
2
Poland
2
Norway
2
Portugal
2
Lithuania
2
Slovenia
2
Hungary
1
Hong Kong
1
Moldova, Republic of
1
RS
1
Russia
1
Croatia
1
Korea, Republic of
1
Cyprus
1
Taiwan
1
Netherlands
1
South Africa
1
Colombia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7335799 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2025
(2 years from now) | |
US11613511 | ESPERION THERAPS INC | Methods of making bempedoic acid and compositions of the same |
Jun, 2040
(17 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10941095 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(6 months from now) | |
US9000041 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(6 months from now) | |
US9624152 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(6 months from now) | |
US10118881 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(6 months from now) | |
US8497301 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(6 months from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 21, 2025 |
Drugs and Companies using BEMPEDOIC ACID ingredient
NCE-1 date: 2024-02-22
Market Authorisation Date: 21 February, 2020
Treatment: Use of nexletol as an adjunct to diet and maximally tolerated statin therapy to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular dise...
Dosage: TABLET;ORAL
25
United States
3
Spain
3
European Union
2
Mexico
2
Japan
2
Hungary
1
Cyprus
1
Brazil
1
Canada
1
Portugal
1
Slovenia
1
Australia
1
Denmark
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7335799 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2025
(2 years from now) | |
US11613511 | ESPERION THERAPS INC | Methods of making bempedoic acid and compositions of the same |
Jun, 2040
(17 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9624152 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(6 months from now) | |
US8497301 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(6 months from now) | |
US9000041 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(6 months from now) | |
US10118881 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(6 months from now) | |
US10941095 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(6 months from now) | |
US10912751 | ESPERION THERAPS INC | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
Mar, 2036
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 21, 2025 |
New Product (NP) | Feb 26, 2023 |
Drugs and Companies using BEMPEDOIC ACID; EZETIMIBE ingredient
NCE-1 date: 2024-02-22
Market Authorisation Date: 26 February, 2020
Treatment: Use of nexlizet as an adjunct to diet and maximally tolerated statin therapy for inhibiting cholesterol synthesis to lower ldl-c in adults with heterozygous familial hypercholesterolemia or establishe...
Dosage: TABLET;ORAL
31
United States
4
Japan
4
European Union
3
Spain
3
Mexico
3
Australia
2
China
2
Russia
2
Brazil
2
Canada
2
Singapore
2
Hungary
1
Philippines
1
Denmark
1
Ukraine
1
Morocco
1
Korea, Republic of
1
Cyprus
1
Chile
1
Portugal
1
South Africa
1
Slovenia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8314117 | BIOHAVEN IRELAND | CGRP receptor antagonists |
Feb, 2031
(7 years from now) | |
US8759372 | BIOHAVEN IRELAND | N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt |
Feb, 2033
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11083724 | BIOHAVEN IRELAND | Rimegepant for CGRP related disorders |
Mar, 2039
(15 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 27, 2025 |
New Indication (I) | May 27, 2024 |
Drugs and Companies using RIMEGEPANT SULFATE ingredient
NCE-1 date: 2024-02-28
Market Authorisation Date: 27 February, 2020
Treatment: Acute treatment of migraine with or without aura in adults; Preventive treatment of episodic migraine in adults
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
18
United States
6
Japan
6
Korea, Republic of
5
European Union
4
Canada
3
Spain
3
Denmark
3
RS
3
Poland
3
China
3
Brazil
3
EA
3
Croatia
3
Israel
3
Portugal
3
Mexico
3
Australia
3
Lithuania
3
Slovenia
3
Hungary
2
Hong Kong
2
Singapore
2
Argentina
2
Norway
2
Cyprus
1
Philippines
1
New Zealand
1
San Marino
1
Peru
1
Chile
1
Taiwan
1
Netherlands
1
South Africa
1
Colombia
1
Tunisia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8835488 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(8 years from now) | |
US11077098 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(8 years from now) | |
US9309234 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9642842 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(8 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Oct 30, 2025 |
Drugs and Companies using OLICERIDINE ingredient
NCE-1 date: 2024-10-30
Market Authorisation Date: 30 October, 2020
Treatment: Management of acute pain by intravenous injection
Dosage: SOLUTION;INTRAVENOUS
11
United States
5
Japan
4
Israel
3
Korea, Republic of
3
European Union
2
Spain
2
Denmark
2
Poland
2
New Zealand
2
Portugal
2
Australia
2
Hungary
1
Hong Kong
1
RS
1
China
1
Brazil
1
Canada
1
EA
1
ME
1
Croatia
1
Cyprus
1
Lithuania
1
Slovenia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8907099 | NEUROCRINE | Nitrocatechol derivatives as COMT inhibitors |
May, 2027
(3 years from now) | |
US8168793 | NEUROCRINE | Nitrocatechol derivatives as COMT inhibitors |
Apr, 2029
(5 years from now) | |
US9630955 | NEUROCRINE | Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor |
Dec, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9550759 | NEUROCRINE | Nitrocatechol derivatives as COMT inhibitors |
Jul, 2026
(3 years from now) | |
US9745290 | NEUROCRINE | Dosage regimen for COMT inhibitors |
Oct, 2027
(4 years from now) | |
US8524746 | NEUROCRINE | Dosage regimen for COMT inhibitors |
Jul, 2029
(6 years from now) | |
US10583130 | NEUROCRINE | Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(6 years from now) | |
US10071085 | NEUROCRINE | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(6 years from now) | |
US10357468 | NEUROCRINE | Medicaments for slowing Parkinson's disease |
May, 2035
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 24, 2025 |
Drugs and Companies using OPICAPONE ingredient
NCE-1 date: 2024-04-24
Market Authorisation Date: 24 April, 2020
Treatment: Method of inhibiting comt in the periphery; Method of treating parkinson's disease; Method of reducing o-methylation of l-dopa; Adjunctive treatment to levodopa/carbidopa in patients with parkinson's ...
Dosage: CAPSULE;ORAL
26
United States
10
Japan
10
European Union
9
Portugal
7
Korea, Republic of
5
Spain
5
Denmark
5
China
5
Russia
5
Canada
4
Poland
4
Brazil
4
Australia
4
Hungary
3
Argentina
3
Norway
3
Cyprus
3
Slovenia
3
Mexico
3
United Kingdom
2
IB
2
Croatia
2
Israel
2
South Africa
2
Lithuania
1
Hong Kong
1
Turkey
1
RS
1
Ukraine
1
New Zealand
1
Netherlands
1
Luxembourg
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7300935 | MYOVANT SCIENCES | Thienopyrimidine compounds and use thereof |
Jan, 2024
(8 months from now) | |
US8058280 | MYOVANT SCIENCES | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
Jan, 2024
(8 months from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8735401 | MYOVANT SCIENCES | Thienopyrimidine compounds and use thereof |
Feb, 2024
(8 months from now) | |
US10350170 | MYOVANT SCIENCES | Solid preparation |
Feb, 2036
(12 years from now) | |
US10449191 | MYOVANT SCIENCES | Treatment of prostate cancer |
Sep, 2037
(14 years from now) | |
US11583526 | MYOVANT SCIENCES | Treatment of prostate cancer |
Sep, 2037
(14 years from now) | |
US10786501 | MYOVANT SCIENCES | Treatment of prostate cancer |
Sep, 2037
(14 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 18, 2025 |
Drugs and Companies using RELUGOLIX ingredient
NCE-1 date: 2024-12-18
Market Authorisation Date: 18 December, 2020
Treatment: Treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent; Treatment of adult patients with advanced prostate cancer
Dosage: TABLET;ORAL
23
United States
11
Japan
9
European Union
6
Australia
5
China
5
Canada
5
Israel
4
Brazil
4
New Zealand
4
Mexico
3
Morocco
3
Argentina
3
EA
2
Spain
2
Denmark
2
Poland
2
Norway
2
Portugal
2
Taiwan
2
Lithuania
2
Slovenia
2
Hungary
1
Hong Kong
1
Malaysia
1
Moldova, Republic of
1
RS
1
Russia
1
Croatia
1
Korea, Republic of
1
Cyprus
1
Netherlands
1
South Africa
1
Colombia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10329260 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(11 years from now) | |
US10125102 | BIOCRYST | Human plasma kallikrein inhibitors |
Apr, 2035
(11 years from now) | |
US10662160 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(16 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11230530 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(11 years from now) | |
US10689346 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(11 years from now) | |
US11618733 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(16 years from now) | |
US11117867 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(16 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 3, 2027 |
New Chemical Entity Exclusivity (NCE) | Dec 3, 2025 |
Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient
NCE-1 date: 2024-12-03
Market Authorisation Date: 03 December, 2020
Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older; Prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and ped...
Dosage: CAPSULE;ORAL
16
United States
4
Japan
4
Australia
3
China
3
Canada
3
Singapore
3
Morocco
3
EA
3
Israel
3
Lithuania
3
European Union
2
Philippines
2
Denmark
2
RS
2
Poland
2
Brazil
2
New Zealand
2
Croatia
2
Korea, Republic of
2
Hungary
1
Uruguay
1
Spain
1
Argentina
1
Norway
1
Peru
1
Chile
1
Portugal
1
Taiwan
1
Mexico
1
Netherlands
1
Colombia
1
Slovenia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10131907 | ALNYLAM PHARMS INC | Glycoconjugates of RNA interference agents |
Aug, 2028
(5 years from now) | |
US8828956 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(5 years from now) | |
US8106022 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(6 years from now) | |
US11060093 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(11 years from now) | |
US10465195 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(11 years from now) | |
US10487330 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(11 years from now) | |
US9828606 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(11 years from now) | |
US10612027 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(12 years from now) | |
US11401517 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(12 years from now) | |
US10612024 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(12 years from now) | |
US11446380 | ALNYLAM PHARMS INC | Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
Oct, 2035
(12 years from now) | |
US10478500 | ALNYLAM PHARMS INC | Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression |
Oct, 2035
(12 years from now) | |
US11261447 | ALNYLAM PHARMS INC | Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
Nov, 2038
(15 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10435692 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Oct 6, 2029 |
New Chemical Entity Exclusivity (NCE) | Nov 23, 2025 |
New Indication (I) | Oct 6, 2025 |
Drugs and Companies using LUMASIRAN SODIUM ingredient
NCE-1 date: 2024-11-23
Market Authorisation Date: 23 November, 2020
Treatment: Treatment of primary hyperoxaluria type 1 (ph1)
Dosage: SOLUTION;SUBCUTANEOUS
68
United States
20
Japan
16
European Union
12
Canada
9
Australia
5
China
5
Singapore
4
Israel
4
Lithuania
4
Hungary
3
Spain
3
Denmark
2
RS
2
Poland
2
EA
2
Norway
2
Croatia
2
Korea, Republic of
2
Portugal
2
Taiwan
2
Jordan
2
Mexico
2
Slovenia
1
Uruguay
1
Dominican Republic
1
Philippines
1
Malaysia
1
Brazil
1
Ukraine
1
Morocco
1
Argentina
1
Peru
1
Chile
1
Costa Rica
1
Ecuador
1
South Africa
1
Colombia
1
Luxembourg
1
Tunisia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9611267 | INCYTE CORP | Substituted tricyclic compounds as FGFR inhibitors |
Jan, 2035
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10131667 | INCYTE CORP | Substituted tricyclic compounds as FGFR inhibitors |
Jun, 2033
(10 years from now) | |
US11466004 | INCYTE CORP | Solid forms of an FGFR inhibitor and processes for preparing the same |
May, 2039
(15 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 17, 2025 |
Orphan Drug Exclusivity (ODE) | Aug 26, 2029 |
New Indication (I) | Aug 26, 2025 |
Drugs and Companies using PEMIGATINIB ingredient
NCE-1 date: 2024-04-17
Market Authorisation Date: 17 April, 2020
Treatment: For the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement; Treatment of p...
Dosage: TABLET;ORAL
15
United States
6
Japan
5
Israel
5
European Union
4
Philippines
4
China
4
Argentina
4
Korea, Republic of
4
Australia
4
Lithuania
4
Hungary
3
Spain
3
Denmark
3
RS
3
Poland
3
Canada
3
Singapore
3
EA
3
New Zealand
3
Croatia
3
Peru
3
Chile
3
Portugal
3
Taiwan
3
Slovenia
2
Malaysia
2
Brazil
2
Ukraine
2
ME
2
Cyprus
2
Costa Rica
2
Ecuador
2
Colombia
1
IB
1
Hong Kong
1
Morocco
1
Norway
1
Mexico
1
Netherlands
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10806743 | BRAINTREE LABS | Method of administering lactitol to reduce plasma concentration of lactitol |
May, 2037
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 12, 2025 |
Drugs and Companies using LACTITOL ingredient
NCE-1 date: 2024-02-13
Market Authorisation Date: 12 February, 2020
Treatment: Method of treating chronic idiopathic constipation in adult patients.
Dosage: FOR SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8188113 | DECIPHERA PHARMS | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jul, 2030
(7 years from now) | |
US8461179 | DECIPHERA PHARMS | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jun, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE48731 | DECIPHERA PHARMS | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jun, 2032
(9 years from now) | |
US11433056 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
US11534432 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
US11529336 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
US11344536 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
US11426390 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
US10966966 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
US11266635 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
US11576904 | DECIPHERA PHARMS | NA |
Aug, 2040
(17 years from now) | |
US11576903 | DECIPHERA PHARMS | NA |
Dec, 2040
(17 years from now) | |
US11612591 | DECIPHERA PHARMS | NA |
Dec, 2040
(17 years from now) | |
US11395818 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
Dec, 2040
(17 years from now) | |
US11185535 | DECIPHERA PHARMS | Amorphous kinase inhibitor formulations and methods of use thereof |
Dec, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 15, 2025 |
Orphan Drug Exclusivity (ODE) | May 15, 2027 |
Drugs and Companies using RIPRETINIB ingredient
NCE-1 date: 2024-05-15
Market Authorisation Date: 15 May, 2020
Treatment: Treatment of gastrointestinal stromal tumor; Method of treating gastrointestinal stromal tumors in patients suffering from grade 2 or grade 3 myalgia while being administered ripretinib daily; Treatme...
Dosage: TABLET;ORAL
44
United States
7
China
7
European Union
6
Korea, Republic of
6
Brazil
6
Australia
5
Canada
4
Japan
3
Israel
3
Taiwan
3
Argentina
3
EA
2
Mexico
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10112942 | LOXO ONCOLOGY INC | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(14 years from now) | |
US10584124 | LOXO ONCOLOGY INC | Crystalline forms |
Oct, 2038
(15 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10137124 | LOXO ONCOLOGY INC | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(14 years from now) | |
US10172851 | LOXO ONCOLOGY INC | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(14 years from now) | |
US10786489 | LOXO ONCOLOGY INC | Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile |
Oct, 2038
(15 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 8, 2025 |
Orphan Drug Exclusivity (ODE) | Sep 21, 2029 |
Drugs and Companies using SELPERCATINIB ingredient
NCE-1 date: 2024-05-08
Market Authorisation Date: 08 May, 2020
Treatment: Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy; Treatment of adult patients with...
Dosage: CAPSULE;ORAL